Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and progressive form of pulmonary hypertension (PH) caused by blood clots that don’t dissolve in the lungs. These clots cause scar-like tissue that clogs up or narrows the small blood vessels in the lungs. The surgical and medical treatment options for CTEPH and their limitations are discussed in this touchRESPIRATORY interview with Dr Gustavo Heresi (Cleveland Clinic, Cleveland, OH, USA) as well as future emerging therapies.
The presentation titled ‘CTEPH – Overview and Treatments’ was presented at the Pulmonary Hypertension Association, June 10-12, 2022
- What are the surgical and medical treatment options and what are their limitations?
- What are the challenges in the future development of medical therapy for CTEPH?
- What are the most exciting emerging therapies for CTEPH?
Disclosures: Gustavo Heresi discloses grant/research support from Bayer Healthcare.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the PHA Hybrid Congress 2022.
Share this Video
Related Videos In Pulmonary Hypertension
Jean Elwing, CHEST 2022: Inhaled treprostinil for pulmonary hypertension due to interstitial lung disease – the INCREASE OLE study
INCREASE OLE was the open-label extension of the INCREASE study (NCT02630316), which investigated the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease. We caught up with Prof. Jean Elwing (UC Health, Cincinnati, OH, USA) to discuss the methodology, inclusion criteria, and safety and tolerability findings from the […]
Marc Simon, CHEST 2022: Clinical benefits with a higher dose of LIQ861 in pulmonary arterial hypertension – analysis of the LTI-301 clinical trial
INSPIRE (LTI-301 clinical trial) was a phase 3 study investigating the long-term safety and tolerability of LIQ861 in patients with pulmonary arterial hypertension (NCT03399604). touchRESPIRATORY were delighted to talk with Dr. Marc Simon (UCSF Health, San Francisco, CA, USA) around the aims, design and eligibility criteria of the LTI-301 clinical trial and the findings from […]
Marc Simon, CHEST 2022: LIQ861 for the treatment of pulmonary arterial hypertension
LIQ861 is an investigational, inhaled dry powder formulation of treprostinil delivered through a device, which currently has tentative approval from the FDA for the treatment of pulmonary arterial hypertension (PAH). touchRESPIRATORY were delighted to talk with Dr. Marc Simon (UCSF Health, San Francisco, CA, USA) about LIQ861 and its potential advantages over conventional formulations of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!